Funded Project Details - FY2021
|Title:|| Glycolytic signaling of p38gamma in breast cancer|
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2021 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
Triple-negative breast cancer (TNBC) does not express estrogen receptor (ER), progesterone receptor (PR) and Her2 as therapeutic targets and consequently has the worst prognosis among all types of breast cancers. Metabolic reprogramming toward aerobic glycolysis (also called the Warburg effect) is a hallmark of cancer, which is further activated in TNBC. Although aerobic glycolysis may be therapeutically targeted, the druggable pathway has not been identified. p38 is a TNBC oncogene and stimula...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.